FDA recently issued a draft guidance addressing the issue of suicidal ideation and behavior that emerges during clinical trials of investigational drugs and biologics. The guidance includes recommendations for assessment and for determining which clinical trial protocols should include assessment procedures.
Public comments will be accepted through October 15, 2012.
